Search Result

Results for "

P2X2/3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Farnesyl Transferase (1) Fluorescent Dye (1) Glutamate Dehydrogenase (GLDH) (1) Guanylate Cyclase (1) Interleukin Related (1) Isotope-Labeled Compounds (1) P2X Receptor (22) P2Y Receptor (1) Reference Standards (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Inflammation/Immunology (8) Metabolic Disease (3) Neurological Disease (10)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136254

BzATP triethylammonium salt Maximum Cited Publications 14 Publications Verification	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium salt acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium salt is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-112461A

NF449 octasodium 4 Publications Verification	P2X Receptor	Cardiovascular Disease
NF449 octasodium is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 octasodium is a G_sα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-15568

A-317491 5 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 is a potent, selective and non-nucleotide antagonist of P2X₃ and P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-14483

AF-353 1 Publications Verification Ro-4	P2X Receptor	Cancer
AF-353 (Ro-4) is a potent, selective and orally bioavailable *P2X3/P2X2/3* receptor antagonist, with a pIC₅₀ of 8.0 for both human and rat P2X3, and with a pIC₅₀** of 7.3 for human P2X2/3 .

HY-137451

Sivopixant 1 Publications Verification S-600918	P2X Receptor	Neurological Disease
Sivopixant (S-600918) is a potent and selective P2X3 receptor antagonist (P2X3 IC₅₀=4.2 nM; P2X2/3 IC₅₀=1100 nM). Sivopixant shows strong analgesic effect .

HY-112461

NF449	P2X Receptor	Cardiovascular Disease
NF449 is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 is a G_sα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-108667

TNP-ATP triethylammonium	P2X Receptor Interleukin Related Fluorescent Dye	Neurological Disease
TNP-ATP triethylammonium is a P2X receptor antagonist with an IC₅₀ of 0.010 μM for P2X₃ and an IC₅₀ of 0.062 μM for *P2X_2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA* autophosphorylation, with a K_i of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X_1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline .

HY-135976

P2X3 antagonist 34	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X3 antagonist 34 is a potent, selective and orally active P2X3 homotrimeric receptor antagonist with IC₅₀s of 25 nM, 92 nM and 126 nM for human P2X3, rat P2X3 and guinea pig P2X3 receptors, respectively. P2X3 antagonist 34 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. P2X3 antagonist 34 has strong anti-tussive effect .

HY-15568A

A-317491 sodium salt hydrate 5 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X₃ and P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-16322

Minodronic acid 1 Publications Verification YM-529	P2X Receptor Apoptosis Farnesyl Transferase	Metabolic Disease Cancer
Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

HY-16322A

Minodronic acid hydrate 1 Publications Verification YM-529 hydrate	P2X Receptor Apoptosis	Metabolic Disease Cancer
Minodronic acid (YM-529) hydrate is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid hydrate induces tumor cell apoptosis and inhibits cell growth. Minodronic acid hydrate also suppresses bone resorption. Minodronic acid hydrate can be used in research related to osteoporosis and cancer .

HY-153548

P2X2/3 modulator-1	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X2/3 modulator-1 (Compound 46) is a *P2X2/3* modulator. P2X2/3 modulator-1 can be used in the study of pain, central nervous system disorders and inflammation .

HY-18745

BzATP triethylammonium Benzoylbenzoyl-ATP triethylammonium	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-19978

RO-3	P2X Receptor	Neurological Disease
RO-3 is a potent, and orally active P2X₃ and *P2X_2/3* antagonist with pIC₅₀s of 5.9 and 7.0 for human homomultimeric P2X₃ and heteromultimeric P2X_2/3 receptors, respectively. RO-3 shows selectivity for P2X₃ and P2X_2/3 over all other functional homomultimeric P2X receptors (IC₅₀ >10 μM at P2X_1,2,4,5,7) .

HY-108673

Ro 0437626	P2X Receptor	Cancer
Ro 0437626 is a selective purinergic (P2X₁) receptor antagonist (IC₅₀ = 3 μM), but shows low affinity for P2X2, P2X3 and P2X2/3 receptors (IC₅₀ > 100 μM) .

HY-137610A

TNP-ATP tetrasodium	P2X Receptor P2Y Receptor	Neurological Disease
TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and *P2X2/3* receptors (IC₅₀ = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors). TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC₅₀ = 100 and 62 nM, respectively). TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED₅₀ = 6.35 µmol/kg) ^[1][2].

HY-14485

Ro-51	P2X Receptor	Neurological Disease
Ro-51 is a potent and selective dual P2X₃/P2X_2/3 antagonist, with IC₅₀ of 2 nM and 5 nM for P2X₃ and P2X_2/3, respectively. Ro-51 can be used for the research for pain .

HY-14483A

AF-353 hydrochloride Ro-4 hydrochloride	P2X Receptor	Cancer
AF-353 hydrochloride is a potent, selective and orally bioavailable *P2X3/P2X2/3* receptor antagonist, with a pIC₅₀ of 8.0 for both human and rat P2X3, and with a pIC₅₀** of 7.3 for human P2X2/3 .

HY-14483R

AF-353 (Standard) Ro-4 (Standard)	P2X Receptor Reference Standards	Cancer
AF-353 (Standard) is the analytical standard of AF-353. This product is intended for research and analytical applications. AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3 .

HY-16322S

Minodronic acid-d4 YM-529-d₄	Isotope-Labeled Compounds P2X Receptor Apoptosis	Metabolic Disease Cancer
Minodronic acid-d₄ (YM-529-d₄) is deuterium labeled Minodronic acid (HY-16322). Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

HY-186112

PSFL2915	P2X Receptor	Inflammation/Immunology
PSFL2915 is a P2X receptor inhibitor with oral effectiveness, with an IC₅₀ of 0.319 μM for human P2X3, 0.261 μM for rat *P2X2/3, and 13.3 μM for human P2X2, and exhibits ~42-fold selectivity for human P2X3* over human *P2X2. PSFL2915 inhibits human P2X3* activation by preventing allosteric tightening of the inner pocket of the head domain required for channel opening, with magnesium-dependent inhibition. PSFL2915 inhibits rat *P2X2/3* and human *P2X2* receptor activation, and has low activity against human P2X1, P2X4, and P2X7 receptors. PSFL2915 can be used for the research of chronic cough .

HY-137609A

TNP-GTP tetrasodium TNP-Guanosine 5'-triphosphate tetrasodium	Glutamate Dehydrogenase (GLDH) P2X Receptor Guanylate Cyclase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
TNP-GTP tetrasodium is a fluorescently labeled GTP (HY-113225) derivative. TNP-GTP tetrasodium can inhibit glutamate dehydrogenase (K_i = 2.7 μM). TNP-GTP tetrasodium is an antagonist of the purinergic *P2X₂* and *P2X_2/3* receptors with IC₅₀ values of 0.4 and 1.2 nM, respectively. TNP-GTP tetrasodium also inhibit rat soluble guanylyl cyclase (K_i = 11 nM) .

Cat. No.	Product Name	Chemical Structure

HY-16322S

Minodronic acid-d4
Minodronic acid-d₄ (YM-529-d₄) is deuterium labeled Minodronic acid (HY-16322). Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

Minodronic acid-d4

Minodronic acid-d₄ (YM-529-d₄) is deuterium labeled Minodronic acid (HY-16322). Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC₅₀ of 3 nM, and also an antagonist of P2X2/3 receptors with an IC₅₀ of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.